Besivance Ophthalmic Solution: Advanced Bacterial Conjunctivitis Treatment
| Product dosage: 5 ml | |||
|---|---|---|---|
| Package (num) | Per flacon | Price | Buy |
| 2 | $22.62 | $45.23 (0%) | 🛒 Add to cart |
| 3 | $19.77 | $67.85 $59.30 (13%) | 🛒 Add to cart |
| 4 | $19.35 | $90.46 $77.39 (14%) | 🛒 Add to cart |
| 5 | $17.69
Best per flacon | $113.08 $88.45 (22%) | 🛒 Add to cart |
Synonyms | |||
Besivance (besifloxacin ophthalmic suspension) 0.6% is a prescription ophthalmic solution specifically formulated for the treatment of bacterial conjunctivitis. As a broad-spectrum fluoroquinolone antibiotic, it is designed to target and eliminate a wide range of ocular pathogens with high efficacy and a favorable safety profile. Its unique suspension formulation enhances corneal contact time, ensuring optimal drug delivery and sustained antimicrobial activity. Trusted by ophthalmologists, Besivance offers a potent therapeutic option for rapid resolution of symptoms and eradication of causative bacteria.
Features
- Active ingredient: Besifloxacin 0.6% (as besifloxacin hydrochloride)
- Pharmaceutical form: Sterile ophthalmic suspension
- Preservative: Benzalkonium chloride 0.01%
- pH: Approximately 6.8 (compatible with the ocular surface)
- Osmolality: Approximately 260-330 mOsm/kg
- Packaged in a 5 mL white low-density polyethylene bottle with a controlled dropper tip
Benefits
- Rapid bactericidal action against both Gram-positive and Gram-negative ocular pathogens, including resistant strains
- Low propensity for developing bacterial resistance due to its dual inhibition of DNA gyrase and topoisomerase IV
- Enhanced ocular bioavailability and prolonged residence time on the eye due to its mucoadhesive polymeric suspension
- Convenient twice-daily dosing regimen, supporting patient adherence and treatment efficacy
- Demonstrated clinical success in reducing clinical resolution time and microbial eradication in bacterial conjunctivitis
- Well-tolerated formulation with minimal systemic absorption, reducing risk of systemic side effects
Common use
Besivance is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans, Corynebacterium pseudodiphtheriticum, Corynebacterium striatum, Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus warneri, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, and Streptococcus salivarius.
Dosage and direction
- Instill one drop into the affected eye(s) twice daily, approximately 8 to 12 hours apart, for 7 days.
- Wash hands thoroughly before use.
- Avoid touching the dropper tip to any surface, including the eye, to prevent contamination.
- If more than one topical ophthalmic product is being used, administer them at least 5 minutes apart.
- Shake well before each use.
Precautions
- Not for injection or oral use.
- Contact lenses should not be worn during the course of treatment.
- Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.
- Contains benzalkonium chloride, which may be absorbed by soft contact lenses and cause eye irritation.
- Discontinue use and consult a healthcare provider if condition worsens, or if a rash or allergic reaction occurs.
- Use with caution in patients with a history of hypersensitivity to other quinolones.
Contraindications
Besivance is contraindicated in patients with a history of hypersensitivity to besifloxacin, to other quinolones, or to any of the components in this medication.
Possible side effect
The most commonly reported ocular adverse reactions in clinical trials (occurring in approximately 1-2% of patients) included:
- Blurred vision
- Eye irritation
- Eye pain
- Eye redness
- Headache
Uncommon but potentially serious side effects may include:
- Allergic reactions (rash, itching, swelling)
- Superinfection (including fungal)
- Corneal deposits (rare)
Drug interaction
Formal drug interaction studies have not been conducted with Besivance. However, as with other topical ophthalmic preparations, systemic absorption is low. The potential for interactions with systemically administered drugs is minimal. If more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.
Missed dose
If a dose is missed, it should be administered as soon as possible. However, if it is almost time for the next dose, skip the missed dose and resume the usual dosing schedule. Do not instill two doses at the same time to make up for a missed dose.
Overdose
Topical overdose of Besivance is unlikely to cause serious symptoms due to minimal systemic absorption. If accidentally ingested, symptomatic treatment is recommended. In case of ocular overdose, flush the eye with warm tap water.
Storage
- Store at 2°C to 25°C (36°F to 77°F).
- Protect from light.
- Keep the bottle tightly closed when not in use.
- Discard the bottle within 28 days of opening.
Disclaimer
This information is intended for medical professionals and should not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this product card.
Reviews
Clinical studies and post-marketing surveillance have demonstrated high efficacy and patient satisfaction with Besivance. In controlled trials, Besivance achieved clinical resolution in bacterial conjunctivitis significantly faster than vehicle, with microbial eradication rates exceeding 90% for many common pathogens. Ophthalmologists frequently report predictable outcomes, good tolerability, and high patient compliance due to the convenient dosing schedule.